Literature DB >> 19728959

Biomarkers in fibromyalgia.

Jacob N Ablin1, Dan Buskila, Daniel J Clauw.   

Abstract

Fibromyalgia is a common pain syndrome characterized by widespread pain, tenderness, and a number of other somatic symptoms and syndromes. Although there was original skepticism that any objective abnormalities would be identified in these individuals, at present there are many that have been reproducibly identified, and most point to dysregulation of central nervous system function as a key underlying pathogenic mechanism in this and related illnesses. This article reviews several objective abnormalities or measures that have been identified or used in fibromyalgia, and indicates which of these may be most promising to eventually use as biomarkers to follow the response to treatment or progress of disease over time.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19728959     DOI: 10.1007/s11916-009-0056-3

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  45 in total

1.  Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition.

Authors:  Nancy Julien; Philippe Goffaux; Pierre Arsenault; Serge Marchand
Journal:  Pain       Date:  2005-03       Impact factor: 6.961

2.  The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals.

Authors:  Jennifer M Glass; Angela K Lyden; Frank Petzke; Phyllis Stein; Gail Whalen; Kirsten Ambrose; George Chrousos; Daniel J Clauw
Journal:  J Psychosom Res       Date:  2004-10       Impact factor: 3.006

3.  Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia.

Authors:  Samuel A McLean; David A Williams; Phyllis K Stein; Richard E Harris; Angela K Lyden; Gail Whalen; Karen M Park; Israel Liberzon; Ananda Sen; Richard H Gracely; James N Baraniuk; Daniel J Clauw
Journal:  Neuropsychopharmacology       Date:  2006-08-23       Impact factor: 7.853

4.  Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli.

Authors:  Luda Diatchenko; Andrea G Nackley; Gary D Slade; Kanokporn Bhalang; Inna Belfer; Mitchell B Max; David Goldman; William Maixner
Journal:  Pain       Date:  2006-07-11       Impact factor: 6.961

5.  The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic.

Authors:  F Wolfe
Journal:  Ann Rheum Dis       Date:  1997-04       Impact factor: 19.103

Review 6.  Pain genes?: natural variation and transgenic mutants.

Authors:  J S Mogil; L Yu; A I Basbaum
Journal:  Annu Rev Neurosci       Date:  2000       Impact factor: 12.449

Review 7.  How do we know that the pain in fibromyalgia is "real"?

Authors:  Richard E Harris; Daniel J Clauw
Journal:  Curr Pain Headache Rep       Date:  2006-12

8.  A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia.

Authors:  Lesley M Arnold; Evelyn V Hess; James I Hudson; Jeffrey A Welge; Sarah E Berno; Paul E Keck
Journal:  Am J Med       Date:  2002-02-15       Impact factor: 4.965

9.  Sex hormones and pain in regularly menstruating women with fibromyalgia syndrome.

Authors:  Akiko Okifuji; Dennis C Turk
Journal:  J Pain       Date:  2006-11       Impact factor: 5.820

10.  Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia.

Authors:  Richard H Gracely; Frank Petzke; Julie M Wolf; Daniel J Clauw
Journal:  Arthritis Rheum       Date:  2002-05
View more
  10 in total

Review 1.  Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria.

Authors:  John McBeth; Matthew R Mulvey
Journal:  Nat Rev Rheumatol       Date:  2012-01-24       Impact factor: 20.543

Review 2.  Juvenile Fibromyalgia: Different from the Adult Chronic Pain Syndrome?

Authors:  Susmita Kashikar-Zuck; Christopher King; Tracy V Ting; Lesley M Arnold
Journal:  Curr Rheumatol Rep       Date:  2016-04       Impact factor: 4.592

3.  Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin.

Authors:  Philip J Mease; Mildred V Farmer; Robert H Palmer; R Michael Gendreau; Joel M Trugman; Yong Wang
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-06       Impact factor: 5.346

4.  Exploring the feasibility and acceptability of a sleep wearable headband among a community sample of chronic pain individuals: An at-home observational study.

Authors:  Zoe Zambelli; Cecilia E Jakobsson; Laura Threadgold; Antonio R Fidalgo; Elizabeth J Halstead; Dagmara Dimitriou
Journal:  Digit Health       Date:  2022-05-11

Review 5.  Patient-Reported Outcomes and Fibromyalgia.

Authors:  David A Williams; Anna L Kratz
Journal:  Rheum Dis Clin North Am       Date:  2016-03-17       Impact factor: 2.670

Review 6.  Pain Mechanisms and Centralized Pain in Temporomandibular Disorders.

Authors:  D E Harper; A Schrepf; D J Clauw
Journal:  J Dent Res       Date:  2016-06-28       Impact factor: 6.116

Review 7.  Transforming pain medicine: adapting to science and society.

Authors:  D Borsook; E Kalso
Journal:  Eur J Pain       Date:  2013-03-07       Impact factor: 3.931

8.  Conditioned pain modulation is associated with common polymorphisms in the serotonin transporter gene.

Authors:  Fredrik Lindstedt; Jonathan Berrebi; Erik Greayer; Tina B Lonsdorf; Martin Schalling; Martin Ingvar; Eva Kosek
Journal:  PLoS One       Date:  2011-03-28       Impact factor: 3.240

9.  The neurologic pain signature responds to nonsteroidal anti-inflammatory treatment vs placebo in knee osteoarthritis.

Authors:  Marina López-Solà; Jesus Pujol; Jordi Monfort; Joan Deus; Laura Blanco-Hinojo; Ben J Harrison; Tor D Wager
Journal:  Pain Rep       Date:  2022-02-16

Review 10.  The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine.

Authors:  Smriti Iyengar; Michael H Ossipov; Kirk W Johnson
Journal:  Pain       Date:  2017-04       Impact factor: 7.926

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.